New thiazole hybrids were synthesized and evaluated for their in vitro cytotoxicity against a panel of human malignant cell lines. The key steps in the synthesis of hybrids 3?7 involved the initial condensation of appropriate aldononitriles with cysteine ethyl ester hydrochloride, followed by subsequent treatment of resulting thiazolines with diazabicycloundecene to form the thiazole ring. Bioisosteres 8 and 14 have been prepared after the stereoselective addition of 2-(trimethylsilyl)thiazole to the hemiacetals obtained by periodate cleavage of terminal diol functionality in the suitably protected d-glucose derivatives. The obtained analogues showed various antiproliferative activities in the cultures of several tumour cell lines. Hybrid 6 was the most potent in HeLa cells, exhibiting more than 10 and 4 times stronger activity than both leads 1 and 2, respectively. The most active compound in Raji cells was hybrid 12, which was nearly 2-fold more potent than the clinical antitumour drug doxorubicin. All analogues were more potent in A549 cells with respect to lead 1, while compounds 6 and 7 were slightly more active than doxorubicin. Preliminary structure?activity relationship analysis revealed that the presence of a cinnamate group at the C-3 position in analogues of type 7 increases the activity of resulting molecular hybrids.
我们合成了新的噻唑杂化物,并评估了它们对一组人类恶性细胞系的体外细胞毒性。合成混合物 3 和 7 的关键步骤是先将适当的醛基硝酸酯与半胱氨酸乙酯盐酸盐缩合,然后用二氮杂双环烯处理生成的噻唑类化合物,形成噻唑环。将 2-(三甲基硅基)噻唑立体选择性加到通过高碘酸盐裂解受适当保护的 d-葡萄糖衍生物中的末端二醇官能团而得到的半缩醛中,制备出了生物异构体 8 和 14。获得的类似物在几种肿瘤细胞系的培养中显示出不同的抗增殖活性。杂交化合物 6 在 HeLa 细胞中的活性最强,分别比先导化合物 1 和 2 强 10 倍和 4 倍以上。在 Raji 细胞中活性最强的化合物是杂交 12 号,其活性比临床抗肿瘤药物多柔比星高出近 2 倍。与先导物 1 相比,所有类似物在 A549 细胞中的活性都更强,而化合物 6 和 7 的活性略高于多柔比星。初步的结构与活性关系分析表明,在第 7 类类似物的 C-3 位上存在肉桂酸基团会提高所产生的分子杂交化合物的活性。